INTRODUCTION
Many cell-surface receptor tyrosine kinases, as well as certain Gprotein-linked receptors, acutely activate phosphatidylinositol 3-kinase (PI 3-kinase), leading to the generation of 3h-polyphosphoinositides [1, 2] . Phosphatidylinositol 3,4,5-trisphosphate [PtdIns (3, 4, 5) P $ ] is the primary product in i o of the receptorstimulated PI 3-kinase, resulting from phosphorylation of PtdIns(4,5)P # [1, 2] . PtdIns(3,4,5)P $ , which subsequently undergoes dephosphorylation by a specific phosphatase to yield PtdIns(3,4)P # , has been suggested to function as an ubiquitious second messenger. A large number of biological processes have been implicated as targets of this particular pathway [3] , including certain intracellular membrane-trafficking systems, such as mastcell secretion [4] and insulin-sensitive GLUT4 glucose transporter translocation to the plasma membrane in muscle and adipocytes [5] .
Recently, work from a number of groups has identified a family of potential target proteins for 3-phosphorylated inositol lipids, which includes GRP1 (general receptor for 3-phosphoinositides), ADP-ribosylation factor (or ARF) nucleotide-binding-site opener (ARNO) and cytohesin-1 [6] [7] [8] [9] . All of these proteins contain a C-terminal pleckstrin homology (PH) domain that binds PtdIns(3,4,5)P $ in preference to
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its proposed role as a putative PtdIns(3,4,5)P $ receptor. To address whether GRP1 binds PtdIns(3,4,5)P $ in i o, we have expressed a chimaera of green fluorescent protein (GFP) fused to the N-terminus of GRP1 in PC12 cells and, using confocal microscopy, examined its resultant localization in live cells. Stimulation with either nerve growth factor or epidermal growth factor (both at 100 ng\ml) results in a rapid, PH-domain dependent, translocation of GFP-GRP1 from the cytosol to the plasma membrane, which occurs with a time course that parallels the production of PtdIns(3,4,5)P $ . This translocation is dependent on the activation of phosphatidylinositol 3-kinase, since it is inhibited by wortmannin (100 nM), LY294002 (50 µM) and by the co-expression with dominant negative p85. Taken together these data strongly suggest that GRP1 interacts in i o with plasma membrane-located PtdIns(3,4,5)P $ and hence constitutes a true PtdIns(3,4,5)P $ receptor.
PtdIns(4,5)P # and PtdIns(3,4)P # , and an N-terminal 200-amino acid region with high similarity to a domain within Sec7, a yeast protein that is required for transport of polypeptides from the endoplasmic reticulum to and through the Golgi membranes [10] . Functionally, this Sec7 domain has been reported to catalyse guanine-nucleotide exchange on the ARF family of small GTPbinding proteins [6, [11] [12] [13] .
Members of the ARF family are key regulators of vesicle trafficking in eukaryotic cells [14] . Of the six mammalian ARF genes, ARF1, the most extensively studied, functions to recruit coat proteins to membranes of the Golgi apparatus [14, 15] , whereas ARF6, the least-well characterized, appears to be localized to the plasma membrane and endosomes where it may regulate some aspect of endocytosis [16] [17] [18] [19] . Indeed a potential interaction between PI 3-kinase and ARF mutants has been suggested based on the characteristic changes of endosome morphology elicited by the specific PI 3-kinase inhibitor wortmannin [20] . The ability of ARFs to regulate such membrane-fusion events may, in part, be due to their ability to stimulate the activity of certain isoforms of phospholipase D (PLD) [21, 22] .
Although cytohesin-1, ARNO and GRP1 all function as exchange factors for ARF1 in itro [6] [7] [8] [9] 23, 24] , they do have distinct specificities with respect to other ARF isoforms. For instance, cytohesin-1 catalyses guanine-nucleotide exchange on ARF3 but not ARF5 [11] , whereas ARNO functions on ARF6 [23] and GRP1 on ARF5 [13] . Of particular importance has been the recent demonstration that PtdIns(3,4,5)P $ can specifically increase the GRP1-catalysed ARF1 guanine-nucleotideexchange activity in itro [13] .
Here we have addressed whether GRP1 does in fact bind PtdIns(3,4,5)P $ in i o. To do this we have cloned the human equivalent of GRP1 from a blood cDNA library. Recombinant GRP1 specifically binds, via its PH domain, the inositol head group of PtdIns(3,4,5)P $ , with a pharmacology consistent with its role as a putative PtdIns(3,4,5)P $ receptor. Importantly we demonstrate that upon stimulation of PC12 cells with either nerve growth factor (NGF) or epidermal growth factor (EGF), GRP1 translocates rapidly to the plasma membrane in response to the activation of PI 3-kinase. This translocation is dependent upon the PH domain and occurs with a time course that parallels the production of PtdIns(3,4,5)P $ .
MATERIALS AND METHODS

Cloning of human blood GRP1
EST01394 (accession no. M79246) was isolated by PCR using sequence-specific primers (sense, 5h-CTTATTGATGACATTG-AGAGGCTGAAATAT-3h, Primer 1 ; antisense, 5h-CAGGTA-GTCCCCAATGACGGTCTTATTTAG-3h, Primer 2) and a human blood cDNA library as template [Strategene no. 938202 ; oligo(dT) and randomly primed]. The PCR was carried out for 30 cycles of 1 min at 95 mC, 1 min at 60 mC and 1 min at 72 mC using High Fidelity Taq DNA polymerase (BoehringerMannheim). The PCR product, after sequencing, was radiolabelled with [α-$#P]dCTP by using a random priming kit (Boehringer-Mannheim). The labelled probe was used to screen 1i10' p.f.u. of the above-mentioned cDNA library. Hybridization was performed in QuickHyb (Strategene) containing 1i10' d.p.m. per ml of $#P-labelled probe for 12 h at 68 mC. The hybridized filters were washed 3 times with 2iSSC (0.15 M NaCl\0.015 M sodium citrate)\0.1 % SDS followed by 3 times with 0.2iSSC\0.1 % SDS, each wash being performed for 15 mins at 65 mC. The washed blots were exposed to X-ray film overnight at k80 mC to pick positive clones. Following secondary and tertiary secreening under identical conditions, one positive plaque was obtained that was subsequently excised and sequenced. This revealed a partial clone lacking the 5h region, which was obtained as a 550 bp fragment by PCR (parameters as described above, cDNA library as template) using Primer 2 against a T7 primer specific for the cDNA library-containing phagemid. After sequencing, this PCR product was attached to the 5h end of the truncated GRP1 cDNA to obtain the full-length clone.
Sub-cloning of GRP1 into pGEX and pEGFP-C1
Primers (sense, 5h-CGCAGATCTATGGATGAAGACGGCG-GCGGCGAG-3h [Primer 3] and antisense, 5h-CGCGTCGACC-TATTTTTTATTGGCAATCCTTCG-3h [Primer 4], containing the underlined BglII and SalI restriction sites) were designed to amplify the entire coding sequence of human GRP1 by PCR using High Fidelity Taq Polymerase. The PCR product was digested with BglII\SalI, gel-purified and cloned into the corresponding restriction sites of pEGFP-C1 (Clontech). The resultant pEGFP-GRP1 construct was fully sequenced prior to use. GRP1 was cloned into pGEX by digestion of pEGFP-GRP1
using BamH1\SalI with the resultant DNA being cloned into the corresponding restriction sites within pGEX4T-3 (Pharmacia).
Construction of the GRP1 deletion mutants
This was achieved using PCR by the following primer combinations, which contained either underlined BglII (sense) or SalI (antisense) restriction sites : for GRP1PH, sense 5h-CGCAGATCTATGCGCGAGGGCTGGCTCCTGAAG-3h and antisense Primer 4 ; for GRP1∆PH, sense Primer 3 and antisense 5h-CGCGTCGACCTAGTCGTTCCCGCTGTCCT-CCGG-3h. PCR cycles were as described above, with the resultant products being digested with the BglII\SalI prior to cloning into the corresponding sites within pEGFP-C1. The resultant plasmids were fully sequenced prior to use. In a similar manner to that described above, pEGFP-GRP1PH and pEGFP-GRP1∆PH were digested with BamHI\SalI and the resultant insert was cloned into the corresponding restriction sites in pGEX4T-3.
Expression and purification of glutathione S-transferase (GST)-fusion proteins
The pGEX plasmids containing the required GRP1 clone were transformed into the Escherichia coli strain BL21 (DE3) to express and purify the corresponding GST fusion protein as follows. Luria-Bertani broth (5 ml) containing ampicillin (100 µg\ml) was inoculated with a single colony of the transformed strain and grown overnight at 37 mC. This was then diluted 1 : 100 in fresh Luria-Bertani broth containing ampicillin and grown, with shaking, at 37 mC until the cell density had reached a D '!! of 0.5 (approx. 3 h). Protein expression was induced with 0.2 mM isopropyl β--thiogalactoside for 3 h at 37 mC, after which cells were collected by centrifugation. The resultant pellet was resuspended in 50 ml ice-cold buffer A (PBS containing 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF and 1 mM β-mercaptoethanol). Cells were lysed by sonication (3i20 s pulses, with 1 min at 4 mC between each sonication) and incubated at 4 mC with 1 % Triton-X 100 for 1 h with gentle mixing prior to the removal of cell debris by centrifugation. A 50 % slurry (1 ml) of glutathione-Sepharose 4B resin (Pharmacia), prewashed with buffer A, was added to the resultant supernatant and incubated at 4 mC overnight with constant shaking. The resin was washed with 3i10 ml of ice-cold buffer A prior to elution of the bound GST-fusion protein with 50 mM Tris\HCl containing 10 mM glutathione (pH 8.0) by incubating with constant mixing for 10 min at room temperature. Protein content of the eluate was estimated by the Bradford method using BSA as a standard.
[
P]Ins(1,3,4,5)P 4 -binding assays
These assays were performed as described previously [25] . An individual binding assay contained 100 mM KCl, 20 mM NaCl, 10 mM Hepes\NaOH (pH 7.0), 1 mM EDTA, 30 000 d.p.m.
[$#P]Ins(1,3,4,5)P % (prepared as in [26] ), 0.5-1.0 µg of GST-GRP1 and various concentrations of competing unlabelled inositol phosphates in a final volume of 0.5 ml. Equilibrium binding was reached by a 15 min incubation at 4 mC after which the receptor-ligand complex was precipitated by addition of 100 µl of 5 mg\ml γ-globulin and 1 ml of 25 % (w\v) polyetheylene glycol. The samples were spun for 10 min prior to removal of the supernatant with the resultant pellet being washed briefly before counting. Phosphatidylinositol 3-kinase-dependent translocation of GRP1 Cell culture and transfection PC12 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10 % fetal calf serum\5 % horse serum\ 100 µg\ml streptomycin\100 units of penicillin\ml (Gibco)\ 10 mM Hepes (pH 7.0). For transfection, 3.5i10& cells, cultured on 22 mm diameter cover slips, were transfected for 2 h with 1 µg of pEGFP-GRP1 in serum-free medium using Tfx-50 (Promega). In all experiments, cells were cultured on collagen-coated dishes, and isolated by trypsin treatment.
Confocal microscopy of transfected PC12 cells
After transfection (18-24 h), cells were serum starved for 2 h before fluorescence analysis at 37 mC in Krebs-Ringer phosphate buffer (136 mM NaCl\4.7 mM KCl\1.25 mM MgSO % \1.25 mM CaCl # \5 mM sodium phosphate) containing 2 mM NaHCO $ and 25 mM Hepes (pH 7.4). Fluorescence imaging was performed with a Leica DM IRBE inverted confocal microscope controlled with TCS-NT4 software (Leica). In some experiments, cells were fixed with 4.5 % paraformaldehyde and mounted on to glass slides with Mowiol containing 2.5 % diazabicyclo[2.2.2]octane (Sigma). Where inhibitors were used, cells were incubated with wortmannin (100 nM) or LY294002 (50 µM) for 10 min prior to agonist stimulation.
RESULTS
Molecular cloning of human GRP1
The expressed-sequence-tagged database (dbEST) was searched using BLAST to identify human DNA sequences similar to mouse brain GRP1. This identified one expressed sequence tag sequence (accession no. M79246) that showed substantial similarity to mouse GRP1. Using this information we designed two oligonucleotide primers, which were used in the PCR to obtain a 261 bp fragment from a human blood cDNA library. This PCR product, after sequencing to confirm its authenticity, was used to GST-GRP1 573p32 GST-GRP1∆PH 25p11 GST-GRP1PH 538p18
probe the human blood cDNA library. One partial cDNA clone was obtained, which lacked 12 bases of the 5h coding sequence ; these were obtained using a PCR-based method (see Materials and methods). The entire nucleotide sequence of this clone has been deposited in the EMBL database (accession no. AJ005197).
Sequence analysis of human GRP1
Human GRP1 contains a 75 nucleotide 5h-untranslated region that includes a possible Kozak's consensus sequence upstream of the first ATG codon. The open reading frame of 1200 bp encodes for a protein of 399 amino acids with a calculated molecular mass of 46.3 kDa. Sequence analysis revealed the predicted protein to be highly homologous with proteins of the brefeldin A-insensitive ARF guanine-nucleotide-exchange factor family, having 98.8, 82.7 and 79.5 % identity with mouse GRP1, human cytohesin-1 and ARNO. The deduced amino acid sequence reveals the presence of three domains, an N-terminal coiled-coil domain (residues 21-59), a central Sec7 domain (residues 76-247) and a C-terminal PH domain (residues 263-380).
Figure 2 EGF-and NGF-stimulated translocation of GFP-GRP1 is dependent on a functional PH domain
PC12 cells were transfected with (A-D) pEGFP-GRP1, (E,F) pEGFP-GRP1∆PH and (G,H)
pEGFP-GRP1PH. After 24 h, cells were serum starved and imaged by laser-scanning confocal microscopy in the absence of agonist (A,C,E,G) or following addition of (B) NGF (100 ng/ml) or (D,F,H) EGF (100 ng/ml). In the case of NGF, images were captured 2.5 min after addition, whereas with EGF images were obtained 1 min after addition. The nuclear localization of GFP-GRP1PH in G and H is due to the small size, which allows free access through the nuclear pore ; this is restricted for the larger 74 kDa GFP-GRP1.
[ 32 P]Ins(1,3,4,5)P 4 -binding to recombinant GRP1
Full-length GRP1 was expressed as a GST-fusion protein in E. coli and purified using glutathione-Sepharose 4B as described in the Materials and methods. Recombinant GRP1 bound Ins(1,3,4,5)P % with nanomolar affinity and a high degree of
Table 2 Inhibition of EGF-stimulated GFP-GRP1 translocation by specific PI 3-kinase inhibitors
Cells were transfected with the pEGFP-GRP1 and cultured for 24 h as described in Figure 2 . In the case of wortmannin (100 nM) and LY294002 (50 µM), these were added 10 min prior to the addition of EGF (100 ng/ml) ; 1 min after EGF addition cells were fixed and mounted as described in Materials and methods. Cells were imaged and the percentage showing GFP-GRP1 at the plasma membrane determined. In the case of dominant negative p85 (∆p85), cells were co-transfected with ∆p85 and pEGFP-GRP1 in a ratio of 4 : 1, fixed and imaged as above. In all cases the number of cells imaged are as shown.
Condition
Cells in which GFP-GRP1 is at the plasma membrane (%) . This is consistent with GRP1 functioning as a PtdIns(3,4,5)P $ receptor since we have predicted previously that a PtdIns(3,4,5)P $ receptor may in fact bind Ins(1,3,4,5)P % in itro [9] , because of the fact that PtdIns(3,4,5)P $ has Ins(1,3,4,5)P % as its inositol head group [with the distinction that the 1-phosphate is not free, as in Ins(1,3,4,5)P % , but is attached via glycerol to the fatty acids]. It would be expected however, that esterification of the 1-phosphate would result in a decrease in binding affinity to an Ins(1,3,4,5)P % receptor, but would not affect, or may even increase, the binding affinity to a PtdIns(3,4,5)P $ receptor. The data described above are consistent with this view, since GRP1 specifically recognizes the 1,3,4,5-phosphate configuration on the inositol ring in preference to the 1,3,4 and 1,4,5 configurations of PtdIns(3,4)P # and PtdIns(4,5)P # , and furthermore it can accommodate a glycerol substitution on the 1-phosphate.
To map this Ins(1,3,4,5)P % -binding site, we constructed GSTfusion proteins comprising either GRP1 lacking the C-terminal PH domain (GST-GRP1∆PH) or just the PH domain itself (GST-GRP1PH). Clearly (see Table 1 ), only GST-GRP1PH bound Ins(1,3,4,5)P % and, importantly, it did so with an affinity and inositol phosphate specificity similar to that of full-length GRP1 (results not shown).
EGF and NGF stimulate a rapid PH domain-dependent translocation of GRP1 to the plasma membrane of PC12 cells
These binding studies in itro suggest that GRP1 may function in i o as a PtdIns(3,4,5)P $ receptor and, to address this more
Figure 3 Time-lapse confocal imaging of the effect of EGF stimulation on the subcellular localization of GFP-GRP1 in PC12 cells
pEGFP-GRP1 was transfected into PC12 cells and a selected cell was imaged 24 h later ; the number in each panel refers to time (s) at which images were collected. EGF (100 ng/ml) was added immediately after collection of the 20 s image. A similar time course of translocation was seen following stimulation with 50 ng/ml EGF (results not shown). Culturing and manipulation of transfected cells was as described in Figure 2 .
directly, we have transfected PC12 cells with a chimaera of green fluorescent protein (GFP) fused to the N-terminus of GRP1. Using laser-scanning confocal microscopy we have studied the resultant localization of GFP-GRP1 in single living cells prior to, and during, stimulation with either EGF or NGF. In unstimulated cells, GFP-GRP1 resides entirely within the cytosol (Figure 2A ), whereas stimulation with either EGF or NGF (both at 100 ng\ml) resulted in a complete translocation of GFP-GRP1 to the plasma membrane ( Figures 2B-2D ). This agonist-dependent translocation required the PH domain of GRP1 as (i) its deletion prevented translocation ( Figures 2E and 2F ) and (ii) a fusion protein between GFP and just the PH domain of GRP1 (amino acids 267-399 ; GFP-GRP1PH) translocated in response to agonist stimulation in a similar manner to full-length GRP1 ( Figures 2G and 2H) .
EGF-and NGF-dependent translocation of GFP-GRP1 requires activation of PI 3-kinase
To examine whether this translocation requires the agonistdependent activation of PI 3-kinase, we preincubated transfected PC12 cells with the chemically unrelated PI 3-kinase inhibitors wortmannin (100 nM) and LY294002 (50 µM). In the presence of either inhibitor, EGF-stimulated translocation of GFP-GRP1 was almost completely inhibited (see Table 2 ). This inhibition also occurred when we co-expressed a dominant negative p85 (∆p85), which blocks the elevation in PtdIns(3,4,5)P $ by uncoupling the ability of activated tyrosine kinase receptors to stimulate PI 3-kinase [27] (Table 2) . Similar data were also obtained with NGF-stimulated GFP-GRP1 translocation (results not shown).
Figure 4 Time-lapse imaging of the effect of NGF stimulation on the subcellular distribution of GFP-GRP1 in PC12 cells
Cells were transfected with pEGFP-GRP1 as described in Figure 3 . The number in each panel refers to the time (s) at which images were collected. NGF (100 ng/ml) was added immediately after collection of the 20 s image. Culturing and manipulation of transfected cells were as described in Figure 2 . Note the distinct time points at which images were captured compared with Figure 3 .
NGF and EGF stimulate GFP-GRP1 translocation with distinct time courses
Stimulation of PC12 cells with either NGF or EGF results in a distinct rate at which these two agonists generate PtdIns(3,4,5)P $ [28] . EGF stimulation causes a rapid transient peak of PtdIns(3,4,5)P $ , which is maximal after approx. 1 min, and decays such that after 15 min its level is slightly elevated above basal [28] . When stimulated with NGF, however, the peak of PtdIns(3,4,5)P $ is not reached until approx. 5 min and, although still transient in nature, remains significantly above basal even after 30 min [28] . We have therefore examined the kinetics of the translocation of GFP-GRP1 using time-lapse confocal microscopy. An initial appearance of GFP-GRP1 at the plasma membrane occurred within 20 s of EGF addition, and was complete within 60 s, at which time most of the cytosolic GFP-GRP1 had translocated (Figure 3) . The EGF-stimulated translocation of GFP-GRP1 was transient in nature, having almost completely returned to the cytosol after approx. 15 min of stimulation. Interestingly, the time course by which NGF stimulated the translocation of GFP-GRP1 was somewhat different (Figure 4) . Following NGF addition, GFP-GRP1 did not appear at the plasma membrane until 1 min after stimulation, and the translocation was complete after approx. 2.5 min, at which time almost all of the cytosolic GFP-GRP1 had translocated. As with EGF, the response to NGF was transient in nature with most of the GFP-GRP1 having returned to the cytosol after approx. 25 min.
Retention of GFP-GRP1 at the plasma membrane is dependent upon the continual activation of PI 3-kinase
The transient nature of the agonist-generated GFP-GRP1 translocation suggests that a continual activation of PI 3-kinase is required to maintain the protein at the plasma membrane. Indeed, time-lapse confocal imaging of cells treated previously for 60 s with EGF demonstrated that addition of wortmannin (100 nM) promoted the rapid displacement of GFP-GRP1 from the plasma membrane back into the cytosol, a process that was initiated after 20 s and was complete within 60 s ( Figure 5 ).
DISCUSSION
Here we have described the cloning and characterization of a human cDNA encoding for a protein that shows a high degree of Figure 5 Time-lapse sequence of the return of GFP-GRP1 to the cytosol following the addition of wortmannin pEGFP-GRP1-transfected cells were stimulated for 60 s with 100 ng/ml EGF (E), and wortmannin (100 nM ; W) was added immediately after capture of the 60 s image. Images were subsequently captured every 10 s. These images are presented as time-lapse movies that can be accessed through the World Wide Web by connection to URL : http ://www.BiochemJ.org/bj/335/bj3350139add.htm. similarity (98.8 % identity) to the mouse brain protein GRP1 [8] .
In itro, recombinant human GRP1 specifically binds, via its PH domain, Ins(1,3,4,5)P % with a nanomolar affinity and a high degree of specificity for the 1,3,4,5-phosphate configuration on the inositol ring. Furthermore, the addition of glycerol or diacetylglycerol to the 1-phosphate of Ins(1,3,4,5)P % , in the form of GroPIns(3,4,5)P $ or diacetyl GroPIns(3,4,5)P $ , respectively, does not dramatically alter their ability to compete with Ins(1,3,4,5)P % for binding to GRP1. These results suggest that GRP1 constitutes a putative PtdIns(3,4,5)P $ receptor, in that, in itro, it (i) specifically recognizes the 1,3,4,5-phosphate configuration on the inositol ring in preference to the 1,4,5 or 1,3,4 configurations of PtdIns(4,5)P # and PtdIns(3,4)P # , respectively, and (ii) can accomodate glycerol substitution on the 1-phosphate. This interpretation is further strengthened by the recent direct demonstration in itro of specific PtdIns(3,4,5)P $ binding to mouse GRP1 [13] .
The results presented here using live-cell imaging clearly demonstrate that upon stimulation of PC12 cells with either NGF or EGF, GFP-GRP1 specifically and rapidly translocates to the plasma membrane, a recruitment that is dependent upon the presence of a functional GRP1 PH domain and the ability of the agonist to stimulate PI 3-kinase. Furthermore, we have shown that the time course by which NGF and EGF induce this translocation parallels the rate, and transient nature, by which these two agonists stimulate the production of PtdIns(3,4,5)P $ [28] . These data, taken together with the pharmacology of Ins(1,3,4,5)P % binding to GRP1 in itro, suggest that GRP1 preferentially binds PtdIns(3,4,5)P $ over PtdIns(3,4)P # [and for that matter PtdIns(4,5)P # ] in i o, a binding that is visualized as the translocation of GFP-GRP1 to the plasma membrane of PC12 cells. Clearly, therefore, this suggests strongly that GRP1 constitutes a true PtdIns(3,4,5)P $ receptor in i o. At present the physiological function of GRP1 remains unclear. The study of Klarlund et al. [13] has clearly demonstrated that GRP1 functions in itro as an exchange factor for ARF1 and ARF5, but apparently not for ARF6. Interestingly, the ARFexchange activity on ARF1 is greatly enhanced by the presence of PtdIns(3,4,5)P $ [13] , data which suggest that not only does PtdIns(3,4,5)P $ function to recruit GRP1 to the plasma membrane but that once there it may also stimulate the catalytic activity. It should be stressed however that a detailed description of the exchange activity of GRP1 on the other isoforms of ARF is lacking, and so the identification of the exact ARF isoform to which GRP1 interacts in i o is at present unknown.
ARF proteins have been implicated in a wide range of vesicletransport and fusion steps along the secretory pathway [14, 15] . These include budding, transport and fusion steps in the Golgi complex, in the endoplasmic reticulum and in the endocytotic and exocytotic pathways [15, 29] . The ability to regulate such membrane-fusion events may in part be a result of ARFs functioning as effective activators of PLD [21, [30] [31] [32] . PLD hydrolyses the non-fusogenic phospholipid phosphatidylcholine to generate choline and phosphatidic acid, the latter of which is a fusogenic lipid [33] . Plasma-membrane-localized PLD activity has been described [34] [35] [36] and it is therefore interesting to speculate that the PtdIns(3,4,5)P $ -induced recruitment and activation of GRP1 may result in a stimulation of PLD via an activation of ARF, resulting in a stimulation of fusion events at the plasma membrane. It is noteworthy that several targets of receptor-activated PI 3-kinase signalling involve plasmamembrane-trafficking systems, including insulin-senstive GLUT4 translocation to the plasma membrane in muscle and adipocytes [5, 37] . In this respect it is therefore tempting to suggest a role for GRP1 in regulating such an event in response to an increase in PtdIns(3,4,5)P $ .
